CN113633650A - 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 - Google Patents
一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 Download PDFInfo
- Publication number
- CN113633650A CN113633650A CN202110985845.0A CN202110985845A CN113633650A CN 113633650 A CN113633650 A CN 113633650A CN 202110985845 A CN202110985845 A CN 202110985845A CN 113633650 A CN113633650 A CN 113633650A
- Authority
- CN
- China
- Prior art keywords
- rare ginsenoside
- ginsenoside compound
- beta
- rare
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title claims description 9
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title claims description 9
- 229930182494 ginsenoside Natural products 0.000 title claims description 9
- 229940089161 ginsenoside Drugs 0.000 title claims description 6
- 230000014616 translation Effects 0.000 title claims description 4
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 claims abstract description 32
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 12
- 230000006866 deterioration Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 8
- 239000002439 beta secretase inhibitor Substances 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 3
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 102000054727 Serum Amyloid A Human genes 0.000 abstract description 7
- 108700028909 Serum Amyloid A Proteins 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种抑制淀粉样蛋白产生的稀有人参皂苷的应用,稀有人参皂苷Compound K在益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品或其作为成分存在于组合物等中的应用。本发明发现稀有人参皂苷Compound K对Aβ42淀粉样蛋白形成的抑制效果好于β分泌酶抑制剂,从而可避免Aβ42淀粉样蛋白形成而影响智力。此外,稀有人参皂苷Compound K还具有一定的提高细胞活性的作用。
Description
技术领域
本发明涉及一种生物活性物质及其应用,尤其涉及一种抑制淀粉样蛋白产生的稀有人参皂苷Compound K的应用,可应用于功能食品、保健品和生物医药制品等领域。
背景技术
稀有人参皂苷Compound K在天然人参和西洋参中是不存在或含量甚微的一种人参皂苷,随着人们对它的活性研究越来越广泛和深入,人们发现稀有人参皂苷Compound K在许多方面都体现了更好的生物活性,如:可诱导肿瘤细胞凋亡起到良好的抗肿瘤作用;作用于透明质酸合成酶促进透明质酸分泌从而起到良好的延缓皮肤干燥、抗皱纹等作用;以及抗过敏、抗炎、保肝等作用。
目前还尚未有关于稀有人参皂苷Compound K在神经退行疾病中的相关研究。
发明内容
为了解决上述技术所存在的不足之处,本发明提供了一种抑制淀粉样蛋白产生的稀有人参皂苷的应用。
为了解决以上技术问题,本发明采用的技术方案是:一种抑制淀粉样蛋白产生的稀有人参皂苷的应用,稀有人参皂苷Compound K在益智、预防智力衰退、防治神经退行疾病等中的应用。
进一步地,稀有人参皂苷Compound K单独用于制备具有抑制Aβ42淀粉样蛋白产生的、益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品。
进一步地,稀有人参皂苷Compound K用于制备具有抑制Aβ42淀粉样蛋白产生的、益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品的组合物。
进一步地,稀有人参皂苷Compound K用于制备β分泌酶或γ分泌酶抑制剂及组合物。
本发明发现稀有人参皂苷Compound K具有抑制细胞产生Aβ42淀粉样蛋白的作用,避免Aβ42淀粉样蛋白形成导致智力减退和神经退行疾病的发病。此外,稀有人参皂苷Compound K还具有提高细胞活性的作用。
附图说明
图1为标准品Aβ42淀粉样蛋白的不同浓度下测定的OD450nm值而制作的标准曲线。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明。
一种抑制淀粉样蛋白产生的稀有人参皂苷的应用。
本发明提供了稀有人参皂苷Compound K在益智、预防智力衰退、防治神经退行疾病中的应用。
包括稀有人参皂苷Compound K用于制备抑制Aβ42淀粉样蛋白产生的、益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品或其组合物。以及稀有人参皂苷Compound K用于制备β分泌酶或γ分泌酶抑制剂及组合物。
其中,由稀有人参皂苷Compound K制备的具有抑制Aβ42淀粉样蛋白产生的、益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品或其组合物可为任何可接受的剂型形式,包括口服剂型形式和外给药剂型形式。口服剂型包括片剂、压片糖果、硬胶囊、软胶囊、口服液、糖浆、颗粒、滴丸、口崩片、缓释片、缓释胶囊、控释片以及控释胶囊等。外给药制剂包括水针、冻干粉针、无菌粉针以及输液等。
(一)人参皂苷Compound K对细胞活力的影响
材料准备:
取对数生长期的细胞,吸去细胞培养液,用0.25%胰酶37℃消化2-3分钟,加2mLDMEM培养液,制成单细胞悬液,显微镜下细胞计数后,用培养液调整细胞浓度至2.5×105个/mL,96孔细胞培养板每孔加入200μL细胞悬液,在37℃、5%二氧化碳浓度的二氧化碳培养箱中培养6小时后,吸出培养液,用37℃预温的DMEM培养液冲洗1次。
实验处理:
实验组:在上述细胞材料中分别加入含有有效浓度分别为5、10和20μg/mL的稀有人参皂苷compound K的DMEM培养液。
对照组:在上述细胞材料中添加培养基。
处理方法:
上述实验组和对照组均每组处理3个复孔,继续培养12h后,每孔加入5mg/mL MTT20μL,继续培养4h后吸弃上清,每孔加入200μL DMSO,在微孔板振荡器上振荡10min直至晶体完全溶解。
将96孔培养板置于酶标仪上,在490nm下测定各孔光密度值,根据各孔光密度值计算细胞活性。
细胞活性的计算公式为:细胞活性%=实验组样品的光密度值/对照组光密度值×100%。
实验结果:
根据酶标仪下测定的各孔光密度值计算细胞活性如表1所示,可知人参皂苷compound K对细胞活力有提高作用。
表1不同浓度人参皂苷compound K对细胞活力的影响
(二)稀有人参皂苷Compound K对Aβ42淀粉样蛋白形成的抑制作用
实验处理:
实验组:取对数生长期的细胞,分别加入含有有效浓度分别为5、10和20μg/mL的稀有人参皂苷Compound K的DMEM培养液。
阴性对照组:向对数生长期细胞中加入DMEM培养液。
阳性对照组:向对数生长期细胞中加入含有有效浓度为20μg/mL的β分泌酶抑制剂Verubecestat的DMEM培养液;Verubecestat是一种有效的、选择性的β分泌酶的抑制剂。
处理方法:
上述组别中每个处理三次重复,所有处理在37℃、5%二氧化碳浓度的二氧化碳培养箱中培养12小时后,收集上清液,用于Aβ42含量的测定。
按照“人β淀粉样多肽42(Aβ42)Elisa试剂盒”的操作要求,进行标准品和供试样品的Aβ42含量测定,制作标准品的标准曲线,根据标准曲线计算出供试样品的Aβ42的含量(pg/ml),供试样品对Aβ42产生的抑制率计算公式为:
抑制率%=(阴性对照Aβ42的含量-实验组或阳性对照组Aβ42的含量)/阴性对照Aβ42的含量x 100%。
实验结果:
表2试剂盒测定的标准品Aβ42淀粉样蛋白的不同浓度的OD值。
根据表2绘制标准品Aβ42淀粉样蛋白的不同浓度下OD值标准曲线,如图1所示。
根据图1中标准曲线得到标准计算公式:
Y=0.0032x+0.1312,
R2=0.9866;
将“人β淀粉样多肽42(Aβ42)Elisa试剂盒”测出的实验组和阳性对照组的OD值代入到公式中,得到相应的Aβ42淀粉样蛋白浓度。
再通过对Aβ42淀粉样蛋白产生的抑制率计算公式,计算实验组和阳性对照组样品对Aβ42淀粉样蛋白产生的抑制率,如表3所示:
表3阳性对照组与实验组对Aβ42淀粉样蛋白产生的抑制率。
结论:根据上述实验结果表明,稀有人参皂苷Compound K对Aβ42淀粉样蛋白的形成具有明显的抑制作用,且抑制效果优于β分泌酶抑制剂(Verubecestat),因此在益智、预防智力衰退、防治神经退行疾病等方面具有有益效果,可应用于益智、预防智力衰退、防治神经退行疾病等的功能食品、保健品和生物医药制品或其组合物等。
上述实施方式并非是对本发明的限制,本发明也并不仅限于上述举例,本技术领域的技术人员在本发明的技术方案范围内所做出的变化、改型、添加或替换,也均属于本发明的保护范围。
Claims (4)
1.一种抑制淀粉样蛋白产生的稀有人参皂苷的应用,其特征在于:所述稀有人参皂苷Compound K在益智、预防智力衰退、防治神经退行疾病中的应用。
2.如权利要求1所述的抑制淀粉样蛋白产生的稀有人参皂苷的应用,其特征在于:所述稀有人参皂苷Compound K在抑制Aβ42淀粉样蛋白产生中的应用。
3.如权利要求1所述的抑制淀粉样蛋白产生的稀有人参皂苷的应用,其特征在于:所述稀有人参皂苷Compound K用于制备β分泌酶或γ分泌酶抑制剂及组合物。
4.如权利要求1-3任一项所述的抑制淀粉样蛋白产生的稀有人参皂苷的应用,其特征在于:所述稀有人参皂苷Compound K单独用于功能食品、保健品和生物医药制品或人参皂苷Compound K作为成分存在于组合物中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110985845.0A CN113633650A (zh) | 2021-08-26 | 2021-08-26 | 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110985845.0A CN113633650A (zh) | 2021-08-26 | 2021-08-26 | 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113633650A true CN113633650A (zh) | 2021-11-12 |
Family
ID=78423920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110985845.0A Pending CN113633650A (zh) | 2021-08-26 | 2021-08-26 | 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113633650A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2565002A1 (en) * | 2004-04-28 | 2005-10-28 | The Trustees Of Columbia University In The City Of New York | Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production |
WO2006019685A2 (en) * | 2004-07-16 | 2006-02-23 | The Trustees Of Columbia University In The City Of New York | Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production |
CN106236761A (zh) * | 2016-07-27 | 2016-12-21 | 陕西巨子生物技术有限公司 | 一种包含稀有人参皂苷c‑k的稀有人参皂苷组合物 |
CN108578702A (zh) * | 2018-05-24 | 2018-09-28 | 深圳以诺生物制药有限公司 | 一种稀有人参皂苷的混合物及其应用 |
CN109758464A (zh) * | 2019-03-21 | 2019-05-17 | 淮阴师范学院 | 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用 |
CN111265536A (zh) * | 2020-03-31 | 2020-06-12 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rk2、CK和PPT的抗肿瘤组合物 |
-
2021
- 2021-08-26 CN CN202110985845.0A patent/CN113633650A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2565002A1 (en) * | 2004-04-28 | 2005-10-28 | The Trustees Of Columbia University In The City Of New York | Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production |
WO2006019685A2 (en) * | 2004-07-16 | 2006-02-23 | The Trustees Of Columbia University In The City Of New York | Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production |
CN106236761A (zh) * | 2016-07-27 | 2016-12-21 | 陕西巨子生物技术有限公司 | 一种包含稀有人参皂苷c‑k的稀有人参皂苷组合物 |
CN108578702A (zh) * | 2018-05-24 | 2018-09-28 | 深圳以诺生物制药有限公司 | 一种稀有人参皂苷的混合物及其应用 |
CN109758464A (zh) * | 2019-03-21 | 2019-05-17 | 淮阴师范学院 | 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用 |
CN111265536A (zh) * | 2020-03-31 | 2020-06-12 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rk2、CK和PPT的抗肿瘤组合物 |
Non-Patent Citations (2)
Title |
---|
周伟等: "稀有人参皂苷compoundK研究进展", 《药学学报》 * |
杨擎等: "基于Nrf2/Keap1信号通路人参皂苷CK靶向调节Aβ分子机制研究", 《中华中医药杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110376366A (zh) | 一种烟酸通过gpr109a受体应用于治疗奶牛乳腺炎的实验方法 | |
KR101286870B1 (ko) | 황기 추출물을 포함하는 대사 촉진 조성물 | |
CN113633650A (zh) | 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 | |
CN116869853A (zh) | 鲟鱼籽肽粉及其制备方法、化妆品组合物 | |
CN116549484B (zh) | 2-羟丙基-β-环糊精或开环葫芦脲在预防或治疗痛风方面的用途 | |
CN109602859B (zh) | 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 | |
CN113679041A (zh) | 稀有人参皂苷及其应用 | |
KR20150080131A (ko) | 목서초 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
CN106924235A (zh) | 松萝酸在制备抗肿瘤药物增敏剂中的应用 | |
KR100573375B1 (ko) | 으름덩굴 종자 추출물을 포함하는 항암 조성물 및 그의제조방법 | |
CN106890189A (zh) | 重楼皂苷在制备抗肿瘤药物增敏剂中的应用 | |
CN105663150B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN106924225A (zh) | 厚朴酚在制备抗肿瘤药物增敏剂中的应用 | |
CN105708845B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN110882236A (zh) | 一种抗肿瘤组合物、治疗癌症的药物制剂及其应用 | |
CN106046071B (zh) | 一种苯丙素类化合物的制备方法 | |
CN105687217B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN106046072B (zh) | 苯丙素类化合物及其药学上可接受的盐和药物组合物 | |
CN114432310B (zh) | 异莲心碱在制备治疗白血病药物中的应用 | |
CN110642867A (zh) | 8-乙烯亚胺-小白菊内酯盐酸盐及其制备方法与应用 | |
CN114366752B (zh) | 巴戟天寡糖5聚糖单体Hex5对骨肉瘤的治疗作用 | |
CN113908183B (zh) | 积雪草总苷在制备乳杆菌增殖促进剂中的应用 | |
KR101986013B1 (ko) | Ml323을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 | |
CN113332296B (zh) | 抗非小细胞肺癌组合物及用途 | |
CN115286574B (zh) | Blvrb酶功能抑制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211112 |